Transcriptomics

Dataset Information

0

Increased Muscleblind levels by chloroquine treatment improves myotonic dystrophy type 1 phenotypes in in vitro and in vivo models


ABSTRACT: Myotonic dystrophy type 1 (DM1) is a life-threatening and chronically debilitating neuromuscular disease caused by the expansion of a CTG trinucleotide repeat in the 3'UTR of the DMPK gene. The mutant RNA forms insoluble structures capable of sequestering RNA binding proteins of the Muscleblind-like (MBNL) family, which ultimately originates phenotypes. In this work we demonstrate that treatment with the anti-autophagic drug chloroquine in Drosophila and mouse (HSALR) models, and patient-derived myoblasts, was sufficient to upregulate MBNL1 and 2 proteins. Extra Muscleblind was functional at the molecular level and improved splicing events regulated by MBNLs in all disease models. In vivo, chloroquine rescued locomotion and average crossectional muscle area, and extended median survival of DM1 flies. In HSALR mice the drug recovered muscular strength and histopathology signs, and reduced myotonia grade. Taken together these results offer a novel means to replenish the critically low levels of MBNLs in DM1.

ORGANISM(S): Homo sapiens

PROVIDER: GSE128844 | GEO | 2019/11/22

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-10-24 | GSE268938 | GEO
2024-10-24 | GSE268937 | GEO
2021-07-20 | GSE146801 | GEO
2012-08-17 | E-GEOD-39911 | biostudies-arrayexpress
2024-08-22 | GSE245815 | GEO
2024-08-22 | GSE245814 | GEO
2024-08-22 | GSE245812 | GEO
2012-08-17 | GSE39911 | GEO
2022-07-31 | GSE173359 | GEO
2013-12-01 | E-GEOD-47794 | biostudies-arrayexpress